Canada markets closed

ARCA biopharma, Inc. (ABIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.1100+0.0300 (+1.44%)
At close: 04:00PM EDT
2.0400 -0.07 (-3.32%)
After hours: 04:17PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.0800
Bid2.0000 x 3200
Ask2.1900 x 1000
Day's Range2.0100 - 2.1400
52 Week Range1.7600 - 2.7000
Avg. Volume35,245
Market Cap30.405M
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-0.6700
Earnings DateMay 01, 2023 - May 05, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2022 financial results and provided a corporate update. In May 2022, the Company retained Ladenburg Th

  • Simply Wall St.

    Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • GlobeNewswire

    James Flynn Joins ARCA biopharma Board of Directors

    WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. “We are pleased to welcome James Flynn to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input on the Company’s Board of Directors, including our process for evaluating strategic options for the Company.” Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium